Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE
出版年份 2016 全文链接
标题
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE
作者
关键词
<sup>177</sup>Lu-DOTATATE, P-NET, PRRT, Long-term follow-up, Toxicity, FDG PET
出版物
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 44, Issue 3, Pages 490-499
出版商
Springer Nature
发表日期
2016-10-05
DOI
10.1007/s00259-016-3533-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A Tale of Two Tumors: Treating Pancreatic and Extrapancreatic Neuroendocrine Tumors
- (2015) Daniel M. Halperin et al. Annual Review of Medicine
- Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course
- (2015) Hendrik Bergsma et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC
- (2015) Stefano Severi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis
- (2015) Seong-Jang Kim et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study
- (2014) Giovanni Paganelli et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
- (2014) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
- (2014) Raghava Kashyap et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation
- (2014) H. Bahri et al. JOURNAL OF NUCLEAR MEDICINE
- The Warburg effect: molecular aspects and therapeutic possibilities
- (2014) Hanh Ngo et al. MOLECULAR BIOLOGY REPORTS
- Neuroendocrine Tumor Biomarkers: Current Status and Perspectives
- (2014) Irvin M. Modlin et al. NEUROENDOCRINOLOGY
- Hematological Toxicity of Combined177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up
- (2014) Murali Kesavan et al. NEUROENDOCRINOLOGY
- Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors
- (2014) Ebrahim S. Delpassand et al. PANCREAS
- Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours
- (2013) Stefano Severi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
- (2013) John J. Zaknun et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- (2013) A. Sabet et al. JOURNAL OF NUCLEAR MEDICINE
- Treatment with the Radiolabelled Somatostatin Analog177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
- (2013) Maddalena Sansovini et al. NEUROENDOCRINOLOGY
- Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System
- (2012) Laura H. Tang et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
- (2012) Santosh K. Gupta et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment
- (2012) M. Sandstrom et al. JOURNAL OF NUCLEAR MEDICINE
- The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
- (2011) Ben Lawrence et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland
- (2011) Andreas Klaus Pfeifer et al. NEUROENDOCRINOLOGY
- 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors
- (2010) T. Binderup et al. CLINICAL CANCER RESEARCH
- Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
- (2010) Phillip G. Claringbold et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors
- (2009) E. Garin et al. JOURNAL OF NUCLEAR MEDICINE
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- (2009) M. G. Vander Heiden et al. SCIENCE
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
- (2008) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival
- (2008) Dik J. Kwekkeboom et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastroenteropancreatic neuroendocrine tumours
- (2008) Irvin M Modlin et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started